• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

    4/26/22 8:00:00 AM ET
    $EXEL
    $MYOV
    $PHAT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EXEL alert in real time by email

    FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors. Mr. Karbe, who most recently served as President and Chief Financial Officer of Myovant Sciences, Inc. (NYSE:MYOV), brings over twenty-five years of financial and life-sciences expertise to Phathom.   

    "We are thrilled to welcome Frank to our Board as we approach a critical inflection point for Phathom," said Terrie Curran, President and Chief Executive Officer of Phathom. "Frank's financial, business development, and corporate strategy expertise and strong record of readying organizations for commercialization will help guide the execution of our strategic vision."

    As President and Chief Financial Officer of Myovant, Mr. Karbe led the company's efforts to raise approximately $2 billion in capital and its evolution from a private start-up organization to a publicly listed commercial-stage company with two approved and marketed products. Prior to Myovant, Mr. Karbe served as Executive Vice President and Chief Financial Officer at Exelixis, Inc. (NASDAQ:EXEL), where he drove the biopharma company's transformation from discovery to commercialization. Earlier in his career, he worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. Mr. Karbe has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc. Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.

    About Phathom

    Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company's website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

    CONTACTS

    Media and Investor Contact:

    Nick Benedetto

    1-877-742-8466

    [email protected]

    [email protected]



    Primary Logo

    Get the next $EXEL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXEL
    $MYOV
    $PHAT

    CompanyDatePrice TargetRatingAnalyst
    Exelixis Inc.
    $EXEL
    10/21/2025$48.00Market Perform → Outperform
    Leerink Partners
    Exelixis Inc.
    $EXEL
    9/19/2025$40.00Equal Weight
    Barclays
    Exelixis Inc.
    $EXEL
    9/17/2025$40.00Equal Weight
    Barclays
    Exelixis Inc.
    $EXEL
    9/17/2025$47.00Buy
    Goldman
    Exelixis Inc.
    $EXEL
    7/8/2025$45.00 → $50.00Outperform → Sector Perform
    RBC Capital Mkts
    Exelixis Inc.
    $EXEL
    6/24/2025$60.00Equal-Weight → Overweight
    Stephens
    Exelixis Inc.
    $EXEL
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    Phathom Pharmaceuticals Inc.
    $PHAT
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EXEL
    $MYOV
    $PHAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

    7/15/22 4:38:40 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $MYOV
    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Research & Development Aftab Dana was granted 50,673 shares, increasing direct ownership by 8% to 713,161 units (SEC Form 4)

    4 - EXELIXIS, INC. (0000939767) (Issuer)

    10/10/25 6:57:17 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Financial & Bus. Officer Narula Sanjeev was granted 144,000 shares (SEC Form 4)

    4/A - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    10/8/25 5:09:21 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial & Bus. Officer Narula Sanjeev

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    10/7/25 5:25:12 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $MYOV
    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exelixis upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Exelixis from Market Perform to Outperform and set a new price target of $48.00

    10/21/25 7:13:23 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/19/25 7:43:42 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays resumed coverage on Exelixis with a new price target

    Barclays resumed coverage of Exelixis with a rating of Equal Weight and set a new price target of $40.00

    9/17/25 8:02:00 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $MYOV
    $PHAT
    SEC Filings

    View All

    $EXEL
    $MYOV
    $PHAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EXEL
    $MYOV
    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

    8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

    10/6/25 8:05:23 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exelixis Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXELIXIS, INC. (0000939767) (Filer)

    8/29/25 5:10:41 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.

    SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    8/28/25 4:30:04 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the

    10/21/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

    DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the appointments of Charles "Chip" R. Romp and Tom J. Heyman to its Board of Directors. These appointments further align SynOx's business with its forward strategy as the company nears topline data for emactuzumab and continues its focus on regulatory and commercial activities. In August 2025, SynOx completed enrollment in the Phase 3 TANGENT clinical trial; topline data are expected in the first quarter of 2026. Ray Barlow, Chief Execu

    10/21/25 7:00:00 AM ET
    $AKRO
    $EXEL
    $LEGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/23/25 4:06:35 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/15/25 4:17:38 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    5/13/25 4:13:04 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $MYOV
    $PHAT
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

    Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President

    10/6/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development

    – Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu

    8/29/25 5:47:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXEL
    $MYOV
    $PHAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

    SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    11/4/24 11:20:50 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc.

    SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    8/22/24 4:05:55 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

    6/6/24 1:59:25 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXEL
    $MYOV
    $PHAT
    Financials

    Live finance-specific insights

    View All

    Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the

    10/21/25 4:05:00 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

    Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A

    10/20/25 8:00:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked

    8/7/25 6:59:20 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care